

DESCRIPTION

Title of Invention: NEW CRYSTAL OF PIPERAZINE COMPOUND

Technical Field

5 [0001]

Cross Reference to Related Applications

This application claims priority to Japanese Patent Application No. 2015-184022, filed on September 17, 2015, the entire contents of which are herein incorporated by reference.

10

The present invention relates to a novel crystal of a piperazine compound. More specifically, the present invention relates to a novel crystal of a piperazine compound that can be stably provided as a crystal of an active pharmaceutical ingredient for use in the manufacture of medicines, while ensuring sufficient reproducibility, and that has excellent storage stability; and the invention relates to a useful pharmaceutical composition containing the crystal as an active ingredient.

20

Background Art

[0002]

In general, when a compound is used as an active ingredient of a pharmaceutical product, it is necessary to stably obtain a single crystal having a constant quality while ensuring sufficient reproducibility. Further, it is preferred that the resulting single crystal has excellent stability.

25


[0003]

Patent Document 1 discloses, as a compound having a prostaglandin D synthase inhibiting action, 4-((1-methylpyrrol-2-yl)-carbonyl)-N-(4-(4-morpholin-1-yl-carboxylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide (which hereinafter may also be referred to as "Compound (1)") represented by Formula (1) below.

30

[0004]

35



[0005]

Patent Document 1 discloses that Compound (1) exhibits  
5 a hematopoietic prostaglandin D synthase (H-PGDS) inhibiting  
effect in humans. Compound (1) is currently clinically developed.

[0006]

The method for producing Compound (1) disclosed in  
Patent Document 1 comprises purification of an obtained reaction  
10 product using silica-gel column chromatography. The obtained  
compound was in the form of a foamy substance (amorphous).

[0007]

Further, Patent Document 2 discloses a formulation  
example of a monohydrate of Compound (1).

15 [0008]

As described above, preferable crystal forms of  
Compound (1) as a crystal of an active pharmaceutical ingredient  
for use in the manufacture of pharmaceutical products have been  
completely unknown.

20

#### Citation List

##### Patent Documents

[0009]

Patent Document 1: WO2010/104024

25 Patent Document 2: WO2014/046129

#### Summary of Invention

##### Technical Problem

[0010]

An object of the present invention is to provide a crystal of Compound (1) having a prostaglandin D synthase inhibiting action that has excellent storage stability as an active pharmaceutical ingredient for use in the manufacture of pharmaceutical products, and preferably that can be obtained with sufficient reproducibility.

Solution to Problem

[0011]

The inventors of the present invention conducted extensive research to attain the above object, and succeeded in obtaining novel crystal I by performing recrystallization at a temperature equal to or higher than room temperature by using an organic solvent that has been generally used for a crude product of Compound (1), such as an alcohol or ketone-based solvent. The inventors also succeeded in obtaining novel crystal II by performing suspension washing of Compound (1) at a temperature of 100°C or more by using a generally used organic solvent. More specifically, the inventors found novel crystals I and II having excellent absorbability and stability, and found, in particular, that crystal I has excellent storage stability and can be obtained while ensuring sufficient reproducibility. With this finding, the inventors completed the present invention.

[0012]

Specifically, the present invention provides Items 1 to 5 below.

1. A crystal of monohydrate of 4-((1-methylpyrrol-2-yl)-carbonyl)-N-(4-(4-morpholin-1-yl-carboxylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide having at least 2 peaks of diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a powder X-ray diffraction spectrum.

2. The crystal according to Item 1, wherein the crystal has at

least 5 peaks of diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a powder X-ray diffraction spectrum.

- 5     3. The crystal according to Item 1 or 2, wherein the crystal is characterized by the powder X-ray diffraction spectrum shown in Fig. 1.
4. The crystal according to any one of Items 1 to 3, wherein the  
10    crystal has an endothermic peak at  $170^\circ\text{C} \pm 5^\circ\text{C}$  in differential scanning calorimetry analysis.  
[0013]
5. The crystal according to any one of Items 1 to 4, wherein the crystal is characterized by the differential scanning calorimetry  
15    (DSC) curve shown in Fig. 2 in differential scanning calorimetry analysis.
6. A crystal of monohydrate of 4-((1-methylpyrrol-2-yl)-carbonyl)-N-(4-(4-morpholin-1-yl-carboxylpiperidin-1-yl)-phenyl)-  
20    1-piperazinecarboxamide produced by a method using a solvent selected from ester-based solvents, ketone-based solvents, alcohol-based solvents, acetonitrile, water, and mixed solvents thereof in crystallization.
- 25    7. The crystal according to Item 6, wherein the crystal is produced by a method using a solvent selected from alcohol-based solvents, water, and mixed solvents thereof in crystallization.
8. The crystal according to Item 6 or 7, wherein the crystal is  
30    produced by a method using a solvent selected from ethanol, water, and mixed solvents thereof in crystallization.
9. The crystal according to Items 6 to 8, wherein the crystal is produced by a method using a mixed solvent of ethanol and water  
35    in crystallization.

10. The crystal according to Items 6 to 9, wherein the crystal has at least 2 peaks of diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a powder X-ray diffraction spectrum.

11. The crystal according to Items 6 to 10, wherein the crystal has at least 5 peaks of diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a powder X-ray diffraction spectrum.

12. The crystal according to any one of Items 6 to 11, wherein the crystal is characterized by the powder X-ray diffraction spectrum shown in Fig. 1.

13. The crystal according to any one of Items 6 to 12, wherein the crystal has an endothermic peak at  $170^\circ\text{C} \pm 5^\circ\text{C}$  in differential scanning calorimetry analysis.

14. The crystal according to any one of Items 6 to 13, wherein the crystal is characterized by the differential scanning calorimetry (DSC) curve shown in Fig. 2.

[0014]

15. A pharmaceutical composition comprising the crystal according to any one of Items 1 to 14.

16. A method for producing a crystal of monohydrate of 4-((1-methylpyrrol-2-yl)-carbonyl)-N-(4-(4-morpholin-1-yl)-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide, the method using a solvent selected from ester-based solvents, ketone-based solvents, alcohol-based solvents, acetonitrile, water, and mixed solvents thereof in crystallization.

17. The method according to Item 16, wherein the method uses a solvent selected from alcohol-based solvents, water, and mixed

solvents thereof in crystallization.

18. The method according to Item 16 or 17, wherein the method  
uses a solvent selected from ethanol, water, and mixed solvents  
5 thereof in crystallization.

19. The method according to Items 16 to 18, wherein the method  
uses a mixed solvent of ethanol and water in crystallization.

10 20. The method according to Items 16 to 19, wherein the method is  
a method for producing a crystal having at least 2 peaks of  
diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  
 $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a powder X-ray  
diffraction spectrum.

15

21. The method according to Items 16 to 20, wherein the method is  
a method for producing a crystal having at least 5 peaks of  
diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  
 $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a powder X-ray  
20 diffraction spectrum.

22. The method according to any one of Items 16 to 21, wherein  
the method is a method for producing a crystal characterized by  
the powder X-ray diffraction spectrum shown in Fig. 1.

25

23. The method according to any one of Items 16 to 22, wherein  
the method is a method for producing a crystal having an  
endothermic peak at  $170^\circ\text{C} \pm 5^\circ\text{C}$  in differential scanning  
calorimetry analysis.

30

24. The method according to any one of Items 16 to 23, wherein  
the method is a method for producing a crystal characterized by  
the differential scanning calorimetry (DSC) curve shown in Fig. 2  
in differential scanning calorimetry analysis.

35

## Advantageous Effects of Invention

[0015]

The present invention makes it possible to obtain a novel crystal of Compound (1) that can be obtained with sufficient reproducibility and that has excellent storage stability. The novel crystal of Compound (1) may be used as an active pharmaceutical ingredient for use in the manufacture of medicines.

## Brief Description of Drawings

[0016]

Fig. 1 shows a powder X-ray diffraction spectrum of crystal I (the vertical axis represents intensity (counts). The horizontal axis represents diffraction angle ( $2\theta \pm 0.2^\circ$ )).

Fig. 2 shows a differential scanning calorimetry (DSC) curve of crystal I. The horizontal axis represents temperature ( $^\circ\text{C}$ ). The vertical axis represents heat flow, endothermic, downward (mW). peak X =  $169.89^\circ\text{C}$

Fig. 3 shows infrared absorption spectrum (IR) of crystal I.

Fig. 4 shows a fingerprint region of an infrared absorption spectrum (IR) of crystal I.

Fig. 5 shows a powder X-ray diffraction spectrum of crystal II (the vertical axis represents intensity (counts). The horizontal axis represents diffraction angle ( $2\theta \pm 0.2^\circ$ )).

Fig. 6 shows a differential scanning calorimetry (DSC) curve of crystal II. The horizontal axis represents temperature ( $^\circ\text{C}$ ). The vertical axis represents heat flow, endothermic, downward (mW). peak X =  $189.74^\circ\text{C}$

Fig. 7 shows a powder X-ray diffraction spectrum (initial value) of crystal I before a solid stability test (under exposure to light) (the vertical axis represents intensity (counts), and the horizontal axis represents diffraction angle ( $2\theta \pm 0.2^\circ$ )).

Fig. 8 shows a powder X-ray diffraction spectrum (a

value after irradiation at 3500000 lux/h) of crystal I after a solid stability test (under exposure to light) (the vertical axis represents intensity (counts), and the horizontal axis represents diffraction angle ( $2\theta \pm 0.2^\circ$ )).

5                Fig. 9 shows a powder X-ray diffraction spectrum (initial value) of crystal II before a solid stability test (under exposure to light) (the vertical axis represents intensity (counts), and the horizontal axis represents diffraction angle ( $2\theta \pm 0.2^\circ$ )).

10              Fig. 10 shows a powder X-ray diffraction spectrum (a value after irradiation at 3500000 lux/h) of crystal II after a solid stability test (under exposure to light) (the vertical axis represents intensity (counts), and the horizontal axis represents diffraction angle ( $2\theta \pm 0.2^\circ$ )).

15              Fig. 11 shows a dynamic vapor sorption (DVS) system analysis (moisture adsorption-desorption test) of crystal I.

                Fig. 12 shows a dynamic vapor sorption (DVS) system analysis (moisture adsorption-desorption test) of crystal II.

## 20    Description of Embodiments

[0017]

                The present invention is more specifically explained below.

[0018]

25              The present invention relates to a crystal of Compound (1). There are two kinds of crystal of Compound (1) of the present invention: crystal I and crystal II. Although both have excellent oral absorbability, crystal I is more preferable in terms of reproducibility in obtaining crystals, storage stability,

30              and hygroscopic property.

[0019]

                In this specification, the term "crystal" is interpreted according to its general definition and designates a solid having a spatially regular arrangement of its atoms. Such a

35              nature of crystal may be confirmed according to an X-ray

diffraction spectrum.

[0020]

In a powder X-ray diffraction pattern, the diffraction angle and the entire pattern are important in determining the identity of crystals due to the nature of data. Since the relative intensity of a powder X-ray diffraction pattern varies to some extent depending on the direction of crystal growth, the size of the particles, and measurement conditions, the relative intensity should not be strictly interpreted.

10 [0021]

The values obtained from various patterns may contain error to some extent depending on the direction of crystal growth, the size of the particles, measurement conditions, and the like. Therefore, in this specification, the values of diffraction angle ( $2\theta \pm 0.2^\circ$ ) in a powder X-ray diffraction pattern may contain measurement error in a range of about  $\pm 0.2^\circ$ .

15

[0022]

The crystal of Compound (1) of the present invention may be produced through crystallization of amorphous state of Compound (1), or crystallization or recrystallization of a reaction product obtained after the synthesis of Compound (1).

20

[0023]

Examples of Compound (1) to be used for the crystallization method of the present invention include a compound produced by the method disclosed in Patent Document 1. The crystallization may be performed using a liquid containing Compound (1) that results from the synthesis of Compound (1) or crystals (crude crystals) temporarily taken out from the liquid; however, to further improve the purity of the crystals, crystallization is preferably performed using crystals temporarily taken out from the liquid. The crystals to be temporarily removed may be crystal I or crystal II.

30

[0024]

Examples of solvents to be used for the crystallization of crystal I of monohydrate of Compound (1) include, as a single

35

solvent, ethyl acetate, n-propyl acetate, butyl acetate, or like ester-based solvents; acetone, methyl ethyl ketone, methyl isopropyl ketone or like ketone-based solvents; methanol, ethanol, or like alcohol-based solvents; acetonitrile; and the like. As  
5 mixed solvents, mixed solvents of any of the above solvents and water may be used. The solvent is more preferably an alcohol-based solvent, water, and a mixed solvent thereof, further preferably ethanol, water, and a mixed solvent thereof, and particularly preferably a mixed solvent of ethanol and water. The  
10 amount of solvent (v/w) is preferably not less than 5 times and not more than 30 times the amount of Compound (1), more preferably not less than 5 times and not more than 20 times the amount of Compound (1), further preferably not less than 7 times and not more than 15 times the amount of Compound (1). The  
15 dissolution temperature and the crystallization temperature are preferably not less than room temperature and not more than 100°C.  
[0025]

Further, the present invention may otherwise be expressed as crystal I produced by a method characterized by  
20 using a solvent selected from ester-based solvents, ketone-based solvents, alcohol-based solvents, acetonitrile, water, and mixed solvents thereof in crystallization. Furthermore, the present invention may also be expressed as a method for producing crystal I using a solvent selected from ester-based solvents, ketone-  
25 based solvents, alcohol-based solvents, acetonitrile, water, and mixed solvents thereof in crystallization.  
[0026]

To accelerate the crystallization of crystal I of monohydrate of Compound (1), an appropriate amount of crystal I  
30 of monohydrate of Compound (1) or a mixed crystal containing crystal I can be added as seed crystal. The amount of the seed crystal to be added is preferably 0.01 to 5 (w/v)%, and more preferably 0.03 to 1 (w/v)% based on the solvent amount. The crystal containing crystal I herein means a crystal containing  
35 crystal I in an amount of 25% or more. Further, crystallization

may be performed under stirring so as to shorten the crystallization time and control the particle diameter.

[0027]

The precipitated crystals may be isolated and purified  
5 from the solution in which the crystals are dissolved, the mixed solution, or the like, by a known isolation and purification means, such as filtration, washing with an organic solvent, or drying under reduced pressure. Examples of organic solvents to be used for washing include alcohol-based solvents, ketone-based  
10 solvents, and acetonitrile.

[0028]

Crystal I is obtained either through crystallization of Compound (1) by using a single solvent such as an alcohol-based solvent, a ketone-based solvent, or the like, or crystallization  
15 by using a mixed solvent of the above solvent and water. Crystal II may be obtained by suspension washing using a single solvent such as a toluene/xylene-based solvent or an ester-based solvent having a high boiling point; crystal I may be obtained with significantly higher reproducibility than that of crystal II.

20 [0029]

Crystal I of the present invention thus obtained has a powder X-ray diffraction spectrum shown in Fig. 1, and has a crystal structure. The characteristic diffraction angle ( $2\theta \pm 0.2^\circ$ ) of crystal I is at least two, preferably at least five, selected  
25 from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$ . Crystal I further preferably has the powder X-ray diffraction spectrum shown in Fig. 1. Crystal I is a hydrate of Compound (I). In the present invention, a powder X-ray diffraction spectrum may be measured according to the test  
30 conditions shown in the Examples of the present invention.

[0030]

Further, the term "near" used for the peak temperature of the endothermic peak in the differential scanning calorimetry (DSC) curve means substantially the same temperature, and  
35 preferably means a temperature in a range of  $\pm 5^\circ\text{C}$  of the

temperature. The term further preferably means a temperature in a range of  $\pm 2^{\circ}\text{C}$  of the temperature. In the present invention, the differential scanning calorimetry (DSC) curve may be measured in accordance with the test conditions in the Examples in the present invention.

[0031]

Further, Fig. 2 shows a differential scanning calorimetry (DSC) curve of crystal I. Crystal I has an endothermic peak near  $170\pm 5^{\circ}\text{C}$  in a differential scanning calorimetry (DSC) curve, and preferably has the differential scanning calorimetry (DSC) curve shown in Fig. 2.

[0032]

Crystal I thus obtained has, as a characteristic diffraction angle ( $2\theta\pm 0.2^{\circ}$ ), at least two peaks selected from  $12.8^{\circ}$ ,  $15.0^{\circ}$ ,  $17.2^{\circ}$ ,  $19.8^{\circ}$ ,  $21.5^{\circ}$ ,  $21.8^{\circ}$ ,  $22.5^{\circ}$ ,  $25.8^{\circ}$ , and  $27.5^{\circ}$  in a powder X-ray diffraction spectrum, and also has an endothermic peak near  $170\pm 5^{\circ}\text{C}$  in a differential scanning calorimetry (DSC) curve. More preferably, crystal I has, as a characteristic diffraction angle ( $2\theta\pm 0.2^{\circ}$ ), at least five peaks selected from  $12.8^{\circ}$ ,  $15.0^{\circ}$ ,  $17.2^{\circ}$ ,  $19.8^{\circ}$ ,  $21.5^{\circ}$ ,  $21.8^{\circ}$ ,  $22.5^{\circ}$ ,  $25.8^{\circ}$ , and  $27.5^{\circ}$  in a powder X-ray diffraction spectrum, and also has an endothermic peak near  $170\pm 5^{\circ}\text{C}$  in a differential scanning calorimetry (DSC) curve. Crystal I further preferably has a spectrum, such as the one shown in Fig. 1, in a powder X-ray diffraction spectrum, and also has a differential scanning calorimetry (DSC) curve, such as the one shown in Fig. 2.

[0033]

Crystal I thus obtained has, as a characteristic absorption band,  $1645\text{ cm}^{-1}$ ,  $1237\text{ cm}^{-1}$ ,  $1021\text{ cm}^{-1}$ ,  $935\text{ cm}^{-1}$ , and  $742\text{ cm}^{-1}$  in an IR spectrum, and preferably has the IR spectrum shown in Fig. 3, and also has a fingerprint region having the IR spectrum shown in Fig. 4.

[0034]

Further, in crystal I thus obtained, the chemical purity of Compound (1) is 90% or more, which may be measured by

high-performance liquid chromatography (HPLC). In crystal I thus obtained, the chemical purity of Compound (1) is preferably 95% or more, more preferably 99% or more.

[0035]

5           Crystal I of Compound (1) may be any crystal insofar as it contains crystal I. Crystal I may be a single crystal of crystal I or a polymorphic mixture containing other crystals. Crystal I preferably contains crystal I in an amount of 90 wt% or more, more preferably 95% or more.

10   [0036]

          Crystal II has a powder X-ray diffraction spectrum, such as the one shown in Fig. 5. Crystal II has, as a characteristic diffraction angle ( $2\theta \pm 0.2^\circ$ ), two or more, preferably four or more, more preferably six or more, further  
15   preferably nine or more, further preferably ten peaks, selected from  $5.1^\circ$ ,  $10.2^\circ$ ,  $15.3^\circ$ ,  $15.6^\circ$ ,  $18.0^\circ$ ,  $19.0^\circ$ ,  $19.3^\circ$ ,  $20.4^\circ$ ,  $23.8^\circ$ , and  $24.7^\circ$ . Crystal II is a nonhydrate of Compound (I).

[0037]

          Further, Fig. 6 shows a differential scanning  
20   calorimetry (DSC) curve of crystal II. Fig. 6 reveals that crystal II has an endothermic peak near  $190^\circ\text{C} \pm 5^\circ\text{C}$ .

[0038]

          Further, for both crystal I and crystal II, the chemical purity was not decreased even after long-term storage  
25   under exposure to light. A powder X-ray crystal analysis revealed that, although the crystal form of crystal II changed after the storage, the crystal form of crystal I did not change, thereby showing its high storage stability. This showed that crystal I has particularly high storage stability.

30   [0039]

          Further, crystal I is less susceptible to the influence of humidity compared with crystal II, and thereby does not have significant restriction in storage conditions; however, crystal II is more susceptible to the influence of humidity and absorbs  
35   moisture, and thereby changes its weight. Due to such influence

of moisture absorption, there is concern regarding maintaining the quality of crystal II.

[0040]

Further, examples of solvents usable in the  
5 crystallization of crystal II include butyl acetate and like ester-based solvents, methyl isopropyl ketone and like ketone-based solvents, toluene, xylene, and like aromatic hydrocarbons; these solvents may be used as a single solvent or a mixed solvent. The crystallization temperature of crystal II is preferably not  
10 less than 100°C and not more than the boiling point of the solvent.

[0041]

As is clear from the above, both crystal I and crystal II have high oral absorbability and long-term storage stability,  
15 and thus are useful as a raw material of an oral pharmaceutical composition. In particular, crystal I is superior in terms of long-term storage stability and hygroscopic property, as well as in reproducibility in obtaining crystals.

[0042]

20 Crystal I or crystal II of the present invention may be processed, after being pulverized or without being pulverized, into various forms of pharmaceutical composition, for example tablets, capsules, granules, fine granules, powdered drug, dry syrup and like oral preparations, suppositories, inhalation  
25 agents, nasal drops, ointments, patches, aerosols and like external preparations, and injections; of these, oral preparations are preferable. These pharmaceutical compositions may be produced using a pharmaceutically acceptable carrier by a conventional preparation method known to a person skilled in the  
30 art. Oral solid preparations can be prepared as follows. An excipient, optionally together with a binder, disintegrant, lubricant, colorant, taste-masking or flavoring agent, etc., are added to the active ingredient to produce tablets, coated tablets, granules, powdered drugs, dry syrup, capsules, or the like, by  
35 using an ordinary method. Oral liquid preparations are produced

as follows. A taste-masking agent, buffer, stabilizer, flavoring agent, etc. are added to the active ingredient to produce an internal liquid medicine, syrup, or the like by using an ordinary method. Injections are prepared as follows. A pH adjuster, buffer, 5 stabilizer, isotonizing agent, topical anesthetic, etc. are added to the active ingredient to produce a subcutaneous injection, an intramuscular injection, or an intravenous injection by using an ordinary method. Suppositories are prepared as follows. An excipient, and, as necessary, a surfactant etc. are added to the 10 active ingredient to produce a suppository by using an ordinary method. Ointments are prepared as follows. To prepare a paste, cream, or gel, an ordinary base, stabilizer, wetting agent, preservative, and the like, are added as required, and mixed and formulated into drugs by using an ordinary method. Examples of 15 bases include white petrolatum, paraffin, glycerin, cellulose derivatives, polyethylene glycol, silicone and bentonite. Examples of preservatives include methyl parahydroxybenzoate, ethyl parahydroxybenzoate, and propyl parahydroxybenzoate. Patches can be prepared by coating a general support with the 20 above ointment, cream, gel, paste, or the like by using an ordinary method. Suitable examples of supports include woven or nonwoven fabrics made from cotton, staple fibers, and chemical fibers; and films and foam sheets of soft polyvinyl chloride, polyethylene, polyurethane, and the like.

25 [0043]

These pharmaceutical compositions are useful for allergic diseases, inflammatory diseases, myodegeneration diseases, and the like (Patent Document 1).

[0044]

30 The amount of crystal I or II to be incorporated in the pharmaceutical composition may vary depending on the conditions of the patient to whom the pharmaceutical composition is administered, the dosage form thereof, and the like. However, in general, in the case of an oral agent, the amount of crystal I or 35 II is about 0.05 to 1,000 mg per dosage unit form; in the case of

an injection, the amount of crystal I or II is about 0.01 to 500 mg per dosage unit form; and in the case of a suppository or external preparation, the amount of crystal I or II is about 1 to 1,000 mg per dosage unit form. Further, the daily dose of crystal  
5 I or II in the pharmaceutical composition depends on the conditions of the patient, route of administration, age of the patient, and the like, and cannot be generalized. The daily dose is determined according to the doctor's prescription, and is generally about 0.05 to 5,000 mg.

10

#### Examples

[0045]

The present invention is more specifically explained below with reference to Examples; however, the present invention  
15 is not limited to these Examples. The present invention is fully described below by way of examples; however, it is understood that various changes and modifications by a skilled artisan are possible. Therefore, such changes and modifications are included in the present invention as long as they do not depart from the  
20 scope of the invention.

[0046]

The various reagents used in the Examples were obtained from commercial suppliers, unless otherwise specified. NMR spectrum was obtained using AVANCEIII (400 MHz; Bruker BioSpin).  
25 The measurement was performed using tetramethylsilane as the internal reference when tetramethylsilane was contained in the deuterated solvent. In other cases, a NMR solvent was used as the internal reference. All  $\delta$  values were expressed in ppm.

[0047]

30 Each symbol stands for the following.

[0048]

s: singlet

d: doublet

t: triplet

35 q: quartet

dd: double doublet

dt: double triplet

td: triple doublet

tt: triple triplet

5 ddd: double double doublet

ddt: double double triplet

dtd: double triple doublet

tdd: triple double doublet

m: multiplet

10 br: broad

brs: broad singlet

#### Powder X-ray diffraction measurement

15 Powder X-ray diffraction was performed by lightly  
pulverizing an appropriate amount of a test substance as  
necessary using an agate mortar, and measuring the test substance  
in accordance with the following test conditions.

[0049]

Device: PANalytical X'Pert PRO

20 Target: Cu

X-ray tube current: 30 mA

X-ray tube voltage: 40 kV

Scanning range:  $2\theta = 5.0$  to  $40.0^\circ$

Step:  $2\theta = 0.0170$

25 Average time/step: 10.984 s

Variable divergence slit: irradiation length = 15 mm

Handling of the device, including data processing, was  
performed in accordance with the method and procedures specified  
for each device.

30 [0050]

The values obtained from various spectra may vary to  
some extent depending on the direction of crystal growth, the  
size of the particles, measurement conditions, and the like.  
Therefore, the values should not be strictly interpreted.

35 [0051]

Thermal Analysis Measurement (differential scanning calorimetry (DSC) measurement)

DSC measurement was performed in accordance with the following test conditions.

5 [0052]

Device: DSC8000, PerkinElmer Co., Ltd.

Sample: about 1.5 mg

Sample container: aluminum container

Temperature increase rate: increased to 250°C at 10°C/min

10 Atmospheric gas: nitrogen

Handling of the device, including data processing, was performed in accordance with the method and procedures specified for each device.

[0053]

15 Dynamic vapor sorption (DVS) system analysis

Dynamic vapor sorption (DVS) system analysis was performed under the following conditions.

[0054]

Device: VTI SGA-100, TA Instruments

20 Sample: about 10 mg

Measurement temperature: 25°C

RH steps: 5-95-1% RH by 5% RH

Elemental analysis

25 Elemental analysis was performed under the following conditions.

[0055]

Device: Thermo Electron Flash EA 1112 series

30 Handling of the device, including data processing, was performed in accordance with the method and procedures specified for each device.

[0056]

Infrared absorption spectrum (IR)

35 Measurement of infrared absorption spectrum was performed under the following conditions.

[0057]

Device: IR Prestige-21, SHIMADZU

Measurement method: KBr method

Handling of the device, including data processing, was  
5 performed in accordance with the method and procedures specified  
for each device.

[0058]

Example 1

Synthesis of monohydrate of 4-((1-methylpyrrol-2-yl)-carbonyl)-N-  
10 (4-(4-morpholin-1-yl-carboxylpiperidin-1-yl)-phenyl)-1-  
piperazinecarboxamide (crystal I)

Ethanol (2680 g) and water (2100 g) were added to a  
crude product (425 g) of Compound (1) synthesized through the  
15 known method disclosed in Patent Document 1, and the mixture was  
heated to internal temperature of 70°C or more to be dissolved.  
Thereafter, cooling crystallization and stirring under ice  
cooling were performed, and then the resulting crystals collected  
by filtration were dried by heating under reduced pressure,  
20 thereby obtaining crystal I of Compound (1) as white powder.  
Mass of the obtained crystal: 342 g, Yield: 80.5%.

As shown in the powder X-ray diffraction spectrum in  
Fig. 1, 2θ of major peaks were 12.8°, 15.0°, 17.2°, 19.8°, 21.5°,  
25 21.8°, 22.5°, 25.8°, and 27.5°. Further, as shown in the  
differential scanning calorimetry (DSC) curve in Fig. 2, the  
endothermic peak was 169.9°C.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ ppm 1.72-2.12 (4H, m), 2.47-2.78 (3H, m), 3.43-  
30 3.90 (18H, m), 3.80 (3H, s), 6.07-6.16 (1H, m), 6.33-6.39 (1H, m),  
6.44 (1H, brs), 6.69-6.78 (1H, m), 6.86-7.02 (2H, m), 7.19-7.31  
(2H, m)

Further, the elemental analysis resulted as follows and  
35 supports a monohydrate of 4-((1-methylpyrrol-2-yl)-carbonyl)-N-

(4-(4-morpholin-1-yl-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide.

Calculation value: C<sub>27</sub>H<sub>38</sub>N<sub>6</sub>O<sub>5</sub>: C, 61.58; H, 7.27; N, 15.96.,

5 Actual measurement value: C, 61.57; H, 7.30; N, 15.86.

Further, Fig. 3 shows an infrared absorption spectrum, and Fig. 4 shows fingerprint region thereof. It was revealed that characteristic absorption bands are present at 1645 cm<sup>-1</sup>, 1237 cm<sup>-1</sup>,  
10 1021 cm<sup>-1</sup>, 935 cm<sup>-1</sup>, and 742 cm<sup>-1</sup>.

[0059]

#### Example 2

Synthesis of crystal II of 4-((1-methylpyrrol-2-yl)-carbonyl)-N-  
15 (4-(4-morpholin-1-yl-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide

Butyl acetate (100 ml) was added to crystal I of Compound (1) (10.0 g). Thereafter, the mixture was heated under  
20 reflux for four hours using an oil bath set to 135°C, and then left for cooling. The solution was filtered and the resulting crystals were dried by heating under reduced pressure, thereby obtaining crystal II of Compound (1) as white powder.  
Mass of the obtained crystal: 8.97g, Yield: 89.7%.

25

As shown in the powder X-ray diffraction spectrum in Fig. 5, 2θ of major peaks were 5.1°, 10.2°, 15.3°, 15.6°, 18.0°, 19.0°, 19.3°, 20.4°, 23.8°, and 24.7°. Further, as shown in the differential scanning calorimetry (DSC) curve in Fig. 6, the  
30 endothermic peak was 189.7°C.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ ppm 1.72-2.12 (4H, m), 2.47-2.78 (3H, m), 3.43-3.90 (18H, m), 3.80 (3H, s), 6.07-6.16 (1H, m), 6.33-6.39 (1H, m), 6.44 (1H, brs), 6.69-6.78 (1H, m), 6.86-7.02 (2H, m), 7.19-7.31  
35 (2H, m)

Further, elemental analysis resulted as follows and supports 4-((1-methylpyrrol-2-yl)-carbonyl)-N-(4-(4-morpholin-1-yl-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide.

5 Calculation value:  $C_{27}H_{36}N_6O_4$ : C, 63.76; H, 7.13; N, 16.52.  
Actual measurement value: C, 63.69; H, 7.18; N, 16.42.

#### Test Example 1

Solid Stability Test (40°C, under light shielding)

10 Using crystal I obtained in the Examples, the solid stability after storage at 40°C under light shielding was measured.

[0060]

Storage conditions: crystal I was stored at 40°C after being  
15 placed in a light shielding bottle covered with a lid.

Measurement points: after 1 month, after 3 months, after 6 months

The amount of analog in the sample solution was measured by HPLC analysis. Handling of the device, including data  
20 processing, was performed in accordance with the method and procedures specified for each device (device: 2130-2450, HITACHI).

Column: Mightysil RP-18 GP 150-4.6 (5  $\mu$ m)

UV detection: 220 nm

25 Column temperature: 40°C

Column flow rate: 1.0 mL/min

Mobile phase: A: acetonitrile, B: 10 mM phos. buffer

Gradient: Table 1

[0061]

30 Table 1

| T i m e ( m i n ) | A     | B     |
|-------------------|-------|-------|
| 0                 | 2 0 % | 8 0 % |
| 2                 | 2 0 % | 8 0 % |
| 2 0               | 7 0 % | 3 0 % |
| 2 7               | 7 0 % | 3 0 % |
| 2 8               | 2 0 % | 8 0 % |
| 3 5               | 2 0 % | 8 0 % |

[0062]

Table 2 shows measurement of results of chemical purity. The chemical purity of crystal I was not changed after storage at 40°C under light shielding.

[0063]

Table 2

|                | Chemical Purity(%) |
|----------------|--------------------|
| Initial Value  | 99.8               |
| After 1 month  | 99.8               |
| After 3 months | 99.6               |
| After 6 months | 99.9               |

[0064]

## 10 Test Example 2

Solid Stability Test (under exposure to light)

Using crystals I and II obtained in the Examples, the solid stability after storage under exposure to light was measured.

15 [0065]

Storage conditions: crystal I was stored at room temperature under exposure to light after being placed in a transparent glass dish covered with a lid.

Measurement point: after irradiation at 3500000 lux·h

20 (irradiation at 2000 lux × 1750 h)

Storage container: transparent glass dish

The powder X-ray diffraction upon the storage stability test was measured after an appropriate amount of the test substance was lightly pulverized as necessary using an agate mortar under the following test conditions.

[0066]

Device: MiniFlex II, Rigaku Corporation

Target: Cu

X-ray output power: 15 mA, 30 kV

5 Scanning range: 3.0 to 40.0°

Step size: 0.010°

Scanning speed: 2.00°C/min.

Divergence slit: 1.25°

Scatter slit: open

10 Receiving slit: open

Handling of the device, including data processing, was performed in accordance with the method and procedures specified for each device.

[0067]

15 The values obtained from various spectra may vary to some extent depending on the direction of crystal growth, the size of the particles, measurement conditions, and the like. Therefore, the values should not be strictly interpreted.

[0068]

20 The results of powder X-ray crystal analysis of crystals I and II revealed that the crystal form of crystal I was not changed (Figs. 7 and 8), whereas the crystal form of crystal II was changed (Figs. 9 and 10). It was thus revealed that crystal I had excellent storage stability.

25 [0069]

Test Example 3

Dynamic Vapor Sorption (DVS) System Analysis

Hygroscopic properties of crystals I and II obtained in the Examples were confirmed by dynamic vapor sorption (DVS) system analysis.

30

[0070]

The adsorption and desorption data was collected at 5% RH intervals in a range of relative humidity (RH) of 5% to 95%. Before the measurement, the samples were heated under nitrogen purging to 25°C at 1°C/min, followed by drying for up to 6 hours

35

until the weight change in 5 minutes became less than 0.0100%.  
The measurement was performed with equilibration for up to 2  
hours until the weight change in 5 minutes became less than  
0.0100%.

5 [0071]

Figs. 11 and 12 show the results of dynamic vapor  
sorption (DVS) system analysis with regard to crystals I and II.  
[0072]

10 There were no changes in weight due to changes in  
humidity in crystal I; in contrast, a great change in weight due  
to a change in humidity was observed in crystal II. Further, for  
both crystals I and II, the results of powder X-ray crystal  
analysis were not changed before and after moisture adsorption  
and desorption.

15 [0073]

It was thus revealed that crystal I was less  
susceptible to the influence of humidity, compared with crystal  
II.

CLAIMS

1. A crystal of monohydrate of 4-((1-methylpyrrol-2-yl)-  
carbonyl)-N-(4-(4-morpholin-1-yl-carboxylpiperidin-1-yl)-phenyl)-  
5 1-piperazinecarboxamide having at least 2 peaks of diffraction  
angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  $19.8^\circ$ ,  $21.5^\circ$ ,  
 $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a powder X-ray diffraction  
spectrum.
- 10 2. The crystal according to claim 1, wherein the crystal has at  
least 5 peaks of diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  
 $15.0^\circ$ ,  $17.2^\circ$ ,  $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a  
powder X-ray diffraction spectrum.
- 15 3. The crystal according to claim 1 or 2, wherein the crystal is  
characterized by the powder X-ray diffraction spectrum shown in  
Fig. 1.
4. The crystal according to any one of claims 1 to 3, wherein the  
20 crystal has an endothermic peak at  $170^\circ\text{C} \pm 5^\circ\text{C}$  in differential  
scanning calorimetry analysis.
5. The crystal according to any one of claims 1 to 4, wherein the  
crystal is characterized by the differential scanning calorimetry  
25 (DSC) curve shown in Fig. 2 in differential scanning calorimetry  
analysis.
6. A crystal of monohydrate of 4-((1-methylpyrrol-2-yl)-  
carbonyl)-N-(4-(4-morpholin-1-yl-carboxylpiperidin-1-yl)-phenyl)-  
30 1-piperazinecarboxamide produced by a method using a solvent  
selected from ester-based solvents, ketone-based solvents,  
alcohol-based solvents, acetonitrile, water, and mixed solvents  
thereof in crystallization.
- 35 7. The crystal according to claim 6, wherein the crystal is

produced by a method using a solvent selected from alcohol-based solvents, water, and mixed solvents thereof in crystallization.

8. The crystal according to claim 6 or 7, wherein the crystal is  
5 produced by a method using a solvent selected from ethanol, water, and mixed solvents thereof in crystallization.

9. The crystal according to claims 6 to 8, wherein the crystal is  
10 produced by a method using a mixed solvent of ethanol and water in crystallization.

10. The crystal according to claims 6 to 9, wherein the crystal  
has at least 2 peaks of diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  
12.8°, 15.0°, 17.2°, 19.8°, 21.5°, 21.8°, 22.5°, 25.8°, and 27.5°  
15 in a powder X-ray diffraction spectrum.

11. The crystal according to claims 6 to 10, wherein the crystal  
has at least 5 peaks of diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  
12.8°, 15.0°, 17.2°, 19.8°, 21.5°, 21.8°, 22.5°, 25.8°, and 27.5°  
20 in a powder X-ray diffraction spectrum.

12. The crystal according to any one of claims 6 to 11, wherein  
the crystal is characterized by the powder X-ray diffraction  
spectrum shown in Fig. 1.  
25

13. The crystal according to any one of claims 6 to 12, wherein  
the crystal has an endothermic peak at  $170^\circ\text{C} \pm 5^\circ\text{C}$  in differential  
scanning calorimetry analysis.

30 14. The crystal according to any one of claims 6 to 13, wherein  
the crystal is characterized by the differential scanning  
calorimetry (DSC) curve shown in Fig. 2.

15. A pharmaceutical composition comprising the crystal according  
35 to any one of claims 1 to 14.

16. A method for producing a crystal of monohydrate of 4-((1-methylpyrrol-2-yl)-carbonyl)-N-(4-(4-morpholin-1-yl-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide, the  
5 method using a solvent selected from ester-based solvents, ketone-based solvents, alcohol-based solvents, acetonitrile, water, and mixed solvents thereof in crystallization.

17. The method according to claim 16, wherein the method uses a  
10 solvent selected from alcohol-based solvents, water, and mixed solvents thereof in crystallization.

18. The method according to claim 16 or 17, wherein the method  
15 uses a solvent selected from ethanol, water, and mixed solvents thereof in crystallization.

19. The method according to claims 16 to 18, wherein the method  
uses a mixed solvent of ethanol and water in crystallization.

20. The method according to claims 16 to 19, wherein the method  
20 is a method for producing a crystal having at least 2 peaks of diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a powder X-ray diffraction spectrum.

21. The method according to claims 16 to 20, wherein the method  
25 is a method for producing a crystal having at least 5 peaks of diffraction angle ( $2\theta \pm 0.2^\circ$ ) selected from  $12.8^\circ$ ,  $15.0^\circ$ ,  $17.2^\circ$ ,  $19.8^\circ$ ,  $21.5^\circ$ ,  $21.8^\circ$ ,  $22.5^\circ$ ,  $25.8^\circ$ , and  $27.5^\circ$  in a powder X-ray  
30 diffraction spectrum.

22. The method according to any one of claims 16 to 21, wherein  
the method is a method for producing a crystal characterized by  
the powder X-ray diffraction spectrum shown in Fig. 1.

23. The method according to any one of claims 16 to 22, wherein the method is a method for producing a crystal having an endothermic peak at  $170^{\circ}\text{C} \pm 5^{\circ}\text{C}$  in differential scanning calorimetry analysis.

5

24. The method according to any one of claims 16 to 23, wherein the method is a method for producing a crystal characterized by the differential scanning calorimetry (DSC) curve shown in Fig. 2 in differential scanning calorimetry analysis.

10